

Cover Sheet

Trust Board Meeting in Public: Wednesday 9 March 2022

TB2022.020

Title: Quality Impact Assessment (QIA) Policy

Status: For Information

History: Trust Management Executive

Board Lead: Chief Medical Officer, Chief Nursing Officer

Author: Chief Medical Officer

Confidential: No

Key Purpose: Assurance

Executive Summary

- 1. Quality Impact Assessment is a process which is undertaken in order to assess the impact of business cases, service changes and other major consultations on
 - Patient Safety
 - Clinical Effectiveness
 - Patient Experience
 - Staff Experience
 - Equality and Diversity
- 2. The OUH Quality Impact Assessment policy has been updated and has been approved by Trust Management Executive (24 February 2022).
- 3. The key updates made to the policy are:
 - Reference is made to the CQC well-led line of enquiry which states that the impact on quality should be considered when considering changes to clinical services.
 - Addition each year as part of budget setting, the divisions should undertake a QIA on any reduction on their year on year budgets at Directorate level and discuss with the Chief Finance Officer and team, before submitting to Chief Medical Officer (CMO) and Chief Nursing Officer (CNO).
 - Section on responsibility for undertaking QIA is expanded to detail roles of Divisional Teams, Divisional Director sign-off and ongoing monitoring of QIAs.
 - Addition CMO/CNO will hold responsibility for approval of QIAs with risk score above 8 to enable projects/business cases to proceed.
 - Clarification that TME will provide final approval of projects/business cases which include QIAs as part of the planning process.
 - Clarification that list of approved QIAs will be held by Quality Assurance Team.

Recommendations

- 4. The Trust Board is asked to
 - Receive and note the content of the updated QIA Policy.



Title: Quality Impact Assessment (QIA) Policy

Category:	Policy		
Summary:	The purpose of this policy is to set out the responsibilities; process and format to be followed for quality impact assessment.		
Equality Analysis undertaken:	January 2022		
Valid From:			
Date of Next Review:	February 2025		
Approval Date/ Via:	TME		
Distribution:	Trustwide		
Related Documents:	Equality Impact Assessment Policy		
Lead Directors:	Chief Nursing Officer; Chief Medical Officer		
Author(s):	Chief Medical Officer		
Further Information:			
This Document replaces:	Quality Impact Assessment Policy – 26 July 2018		

Contents

	Sheettive Summary	
	/ Impact Assessment (QIA) Policy	
1.	Introduction	5
2.	Policy Statement	5
3.	Scope	5
4.	Aim	5
5.	Definitions	6
Q	uality	6
Q	uality Impact Assessment	6
6.	Responsibilities	6
7.	Policy content	7
W	hen and how often a QIA should be undertaken?	7
W	hat should be considered as part of the impact assessment?	7
8.	Process for raising concerns	8
9.	Training	8
10.	Monitoring Compliance	8
11.	Review	10
12.	References	10
13.	Document History	11
14.	Equality impact analysis	11
App	endix 1 Quality Impact Assessment	13
App	endix 2: Quality Impact Assessment - Escalation proforma	18

Quality Impact Assessment (QIA) Policy

1. Introduction

- 1.1. This policy details the process to be undertaken in order to assess the impact of business cases, service changes and other major consultations on the quality of care we offer patients and consider any impact on our staff wellbeing. It also recommends that each year as part of budget setting, the divisions should undertake a QIA on any reduction on their year on year budgets at Directorate level and discuss with the CFO and team before escalating to CMO and CNO.
- 1.2. The Care Quality Commission also state in their well-led key lines of enquiry that when considering changes to clinical services there should be an assessment on the impact to quality.
- 1.3. Oxford University Hospitals NHS Foundation Trust is committed to provision of high quality, safe care and therefore, the completion and approval of QIA's will ensure that all of the above mentioned activities will have a robust impact assessment enabling teams to act on findings to maintain quality.

2. Policy Statement

2.1. It is the policy of Oxford University Hospitals NHS Foundation Trust ("the Trust") that all of its business cases, service changes (such as where OUH staff treat/care for OUH patients) implementation of new systems (such as information technology (IT) software for patient management) or any other proposed major change, such as across the BOB Integrated Care System, that impact on patient services are evaluated for their impact on quality.

3. Scope

3.1. This policy should be read by all clinical and managerial staff across the Trust. It applies to clinical and non-clinical changes that affect the quality of care to OUH patients as well as to staff when developing business cases, planning service changes and introducing new systems or assessing the impact of budget setting.

4. Aim

4.1. The purpose of this policy is to set out the responsibilities; process and format to be followed when undertaking a quality impact assessment.

There is a separate procedure detailing the process for equality impact assessments.

5. Definitions

Quality

- 5.1. Quality can be defined as embracing three key components:
- Safety there will be no avoidable harm to patients from the healthcare they receive.
- Effectiveness of care the most appropriate treatments, interventions, support and services will be provided at the right time to those patients who will benefit.
- Patient Experience a positive patient's experience will be at the centre of the organisation's approach to quality.

Quality Impact Assessment

5.2. An impact assessment is a continuous process to ensure that possible or actual business plans, changes to use of clinical areas, new information technology (IT) software for patient management or any other proposed business, change or implementation plans that impact on patient services are assessed and the potential consequences on quality of care for patients and any impact on staff are considered and any necessary mitigating actions are outlined in a uniformed way.

6. Responsibilities

- 6.1. The Chief Executive, as Accountable Officer, has ultimate responsibility for quality across the Trust.
- 6.2. Divisional teams are responsible for undertaking quality impact assessments, identifying risks and mitigating actions and submitting quality impact assessments for addition to the QIA process with review and sign-off. These staff are responsible for making any operational arrangements to facilitate key stakeholder engagement, at the beginning of the process, collate key issues arising and collect and monitor impact on quality of any quality measures as indicated
- 6.3. Divisional Directors are accountable for reviewing and signing quality impact assessments undertaken by their teams in their areas/services prior to submission to the finance team, business planning group, or other committees when proposing service changes or introduction of new systems. They will also ensure that the impact on quality on an on-going basis is monitored appropriately. They may delegate responsibility for this, but not accountability.
- 6.4. The Chief Nursing Officer and the Chief Medical Officer are responsible for providing Executive approval for any change based on the QIA (above

a risk score of 8). They may reject the proposals if the mitigations are not found to be effective in reducing the risks that become apparent in the QIA.

6.5. The Trust Management Executive is responsible for final approval of the projects based on the QIA sign-off by the CMO and the CNO. The records of completed quality impact assessments will be held by the Assurance Team. All QIA with a score of 16 or above will be noted at IAC.

7. Policy content

When and how often a QIA should be undertaken?

- 7.1. QIA is a continuous process to help decision makers fully think through and understand the consequences of possible and actual financial and operational initiatives, including those where improved quality is the primary driver of change
- 7.2. QIA must be undertaken as part of the development and proposal stage of developing business plans and should also be reviewed on a regular basis by the project leads, as part of reviewing the actual impact throughout the implementation stage and during the final review after the business plan has been implemented.
- 7.3. The frequency of review will be dependent on the level of risk identified (but will be a minimum of six monthly) and will be documented in the quality impact assessment document (see appendix 1). Divisional Directors will maintain oversight of QIA review, reporting through the Divisional Management and Divisional Performance Review meetings.

What should be considered as part of the impact assessment?

- 7.4. The impact assessment template can be found in appendix 1 and outlines the criteria to be considered:
 - Patient Safety
 - Clinical Effectiveness
 - Patient Experience
 - Staff Experience
 - Equality and Diversity

Quality Impact Assessment (QIA) Policy

Level 1 QIA

(Undertaken by Divisional Team in consultation withother relevant parties – and signed off by Divisional Director or delegate)



Level 2 QIA

Approval by CMO and CNO for all QIAs with a Risk score greater than 8



Trust Management Executive is responsible for final sign-off of projects subject to QIA approval by the CMO and the CNO.

(Those with high risks – 16 or above – to be escalated to the Integrated Assurance Committee)



The approval process for Business Plan/project/ improvement plan must also be followed



Monitor risks during implementation and post implementation for changes

(Divisional Teams)

8. Process for raising concerns

8.1. Where concerns are identified, either through monitoring of clinical outcomes; through risk assessments; or via another route such as staff or patient feedback, theysalbe reviewed through the Divisional team in the first instance. If necessary referred to the Assurance team for potential discussion at TME and inclusion in the risk register.

9. Training

9.1. There is no mandatory training associated with this policy. Ad hoc training sessions based on an individual's training needs will be defined within their annual appraisal orjob plan.

10. Monitoring Compliance

10.1. Compliance with the policy will be monitored in the following ways.

Aspect of compliance or effectiveness being monitored	Monitoring method	Responsibility for monitoring	Frequency of monitoring	Group or committee that will review the findings and monitor completion ofany resulting action plan
QIA is undertaken for each change programme that meets criteria, signed off by relevant clinical leaders including Directorate and Divisional Directors	No business cases to be signed off withoutQIA Audit of businesscases.	Business Planning Group	Six monthly	TME
QIA undertaken is appropriate	Audit of QIA scores and narratives	Divisional teams	Six monthly	ТМЕ
QIA is reviewedby CMO and CNO and signed off	Records held by Assurance Team	Assurance Team	Six monthly	TME
Where QIA risk rating is 16 or above, QIA is referred to Integrated Assurance Committee for further discussion	Review of TMEminutes and corroboration with minutes ofIntegrated Assurance Committee	Assurance Team	Six monthly	IAC

Standard	Source of Assurance/	Responsibility
Quality impact assessments are required to accompany all full business case proposals/ business plans at relevant group e.g. Collaborative Commissioning Congress.	Papers for meetings should be scrutinised. Those submitted without quality impact assessments completed mustbe returned to project lead before being progressed.	Project Lead and relevant Senior Manager/ Executive.
All quality impact assessments are submitted to the Director of Compliance and Assurance for logging.	A spreadsheet of submitted quality impact assessments including level of risk and outcome will be maintained.	Assurance Team
Risk registers contain appropriate risks in relation to the potential impact on business plans	OUH risk registers are reviewed and updates, presented to the Integrated Assurance Committee	All Executives
All assessments judged as having high risk 16 or above) must be referred to Integrated Assurance Committee forfurther scrutiny.	Minutes of committee	Assurance Team

11. Review

11.1. This policy will be reviewed every 3 years.

12. References

12.1. None.

13. Document History

Who? Individuals or Committees	Rationale and/or Method of Involvement
Executive Committee	Discussion February 2022
Trust Management Executive	Discussion and ratification February 2022

14. Equality impact analysis

Have you considered how the Policy will affect people:	Yes	No	How have these groups been included in the development of the Policy?	How will the Policy affect them?
Who have a physical or sensory impairment? Have you consulted with them?	х		No	N/A
With a disability?	Х		No	N/A
Of different gender?	х		No	N/A
Of different ages?	Х		No	N/A
With different racial heritages?	х		No	N/A
With different sexual orientations?	х		No	N/A
Who are pregnant or recently had a baby?	x		No	N/A
With different religions or beliefs?	х		No	N/A
Who are going through gender reassignment or have transitioned?	х		No	N/A
Of different marital/partnership status?	х		No	N/A
Who are carers?	Х		No	N/A
Any other group who may be	Х		No	N/A

affected by this		
policy		

Summary of Analysis

Does the analysis show evidence of:	Yes	No	Please explain your answer
The potential to		X	No impact
discriminate?			
The advancement		X	No impact
of equality of			
opportunity?			
The promotion of		X	No impact
good relations			
between groups?			

Appendix 1 Quality Impact Assessment Quality Impact Assessment

Project Name:	
Accountable Executive:	
Project Manager:	

Clinical Director:

DD sign off:

Clinician / Practitioner completing QIA if different to above:	[if applicable]
--	------------------------

			Likeli	hood		
		1	2	3	4	5
		Rare	Unlikely	Possibl	Likel	Almos
				е	У	t
Co	nsequence					certain
5		5	10	15	20	25
Ca	tastrophic					
4	Major	4	8	12	16	20
3	Moderate	3	6	9	12	15
2	Minor	2	4	6	8	10
1	Negligible	1	2	3	4	5

Extreme risk	0
High risk	0
Moderate risk	0
Low risk	0

		Risk rating								
	Brief description of potential impact	Consequence score	Likelihoo d score	Total risk score	Possible mitigation	Mitigated consequenc e score	Mitigated likelihood score	Mitigated risk score		
Patient safety	Detail any impact the project may have on patient safety. Could there be increased risk of the patient being harmed either physically, mentally or via the environment?	On a scale of 1 to 5 - what is is the impact of the risk occurring?	On a scale of 1 to 5 - what is is the likelihood of the risk occurring?	Correspondin g total rating on the matrix above.	Detail what action will be taken to reduce any negative impact.	What is your adjusted consequence score post mitigation?	What is your adjusted likelihood score post mitigation ?	Correspondin g total rating on the matrix above.		

Quality indicators	Current baseline of indicator	Trigger for escalatio n	Actions to be taken upon breachin g trigger level
How will you measure the healthcare quality? What can indicate a change in the quality?	The current achievemen t level of the indicator.	The trigger level at which the impact is escalated to the Trust .	The set of actions to be taken once the trigger is breached.

	Brief description of potential impact	Consequence score	Likelihoo d score	Total risk score	Possible mitigation	Mitigated consequenc e score	Mitigated likelihood score	Mitigated risk score	Quality indicators	Current baseline	Trigger for escalatio n	Actions to be taken upon breachin g trigger level
Clinical effectiveness	Detail any impact the project may have on the clinical effectiveness of patient care. Appropriate care should be provided at the right time to the patients who will benefit. Could the project prevent this from happening?	On a scale of 1 to 5 - what is is the impact of the risk occurring?	On a scale of 1 to 5 - what is is the likelihood of the risk occurring?	Correspondin g total rating on the matrix above.	Detail what action will be taken to reduce any negative impact.	What is your adjusted consequence score post mitigation?	What is your adjusted likelihood score post mitigation ?	Correspondin g total rating on the matrix above.	How will you measure the healthcare quality? What can indicate a change in the quality?	The current achievemen t level of the indicator.	The trigger level at which the impact is escalated to the Trust .	The set of actions to be taken once the trigger is breached.

	Brief description of potential impact	Consequence score	Likelihoo d score	Total risk score	Possible mitigation	Mitigated consequenc e score	Mitigated likelihood score	Mitigated risk score	Quality indicators	Current baseline	Trigger for escalatio n	Actions to be taken upon breachin g trigger level
Patient experience	Detail any impact the project may have on the patient experience of care delivery. Could the project result in increased waiting times / reduction in patient satisfaction etc.	On a scale of 1 to 5 - what is is the impact of the risk occurring?	On a scale of 1 to 5 - what is is the likelihood of the risk occurring?	Correspondin g total rating on the matrix above.	Detail what action will be taken to reduce any negative impact.	What is your adjusted consequence score post mitigation?	What is your adjusted likelihood score post mitigation ?	Correspondin g total rating on the matrix above.	How will you measure the healthcare quality? What can indicate a change in the quality?	The current achievemen t level of the indicator.	The trigger level at which the impact is escalated to the Trust .	The set of actions to be taken once the trigger is breached.
ехрепепсе												

	Brief description of potential impact	Consequence score	Likelihoo d score	Total risk score	Possible mitigation	Mitigated consequenc e score	Mitigated likelihood score	Mitigated risk score	Quality indicators	Current baseline	Trigger for escalatio n	Actions to be taken upon breachin g trigger level
Staff Experience	Detail any staff experience impact the project may have. Could there be any impact on staff health and safety / operations or work satisfaction?	On a scale of 1 to 5 - what is is the impact of the risk occurring?	On a scale of 1 to 5 - what is is the likelihood of the risk occurring?	Correspondin g total rating on the matrix above.	Detail what action will be taken to reduce any negative impact.	What is your adjusted consequence score post mitigation?	What is your adjusted likelihood score post mitigation ?	Correspondin g total rating on the matrix above.				

	Brief description of potential impact	Consequence score	Likelihood score	Total risk score	Possible mitigation	Mitigated consequence score	Mitigated likelihood score	Mitigated risk score	Quality indicators	Cur
Equality & diversity	Will there be any disproportionat e impact on the grounds of race, sex, disability, age, sexual orientation or religious belief? For example moving a clinical service to location inaccessible by public transport	On a scale of 1 to 5 - what is is the impact of the risk occurring?	On a scale of 1 to 5 - what is is the likelihood of the risk occurring?	Corresponding total rating on the matrix above.	Detail what action will be taken to reduce any negative impact.	What is your adjusted consequence score post mitigation?	What is your adjusted likelihood score post mitigation?	Corresponding total rating on the matrix above.	How will you measure the healthcare quality? What can indicate a change in the quality?	The ach leve indi

Quality indicators	Current baseline	Trigger for escalation	Actions to be taken upon breaching trigger level
How will you measure the healthcare quality? What can indicate a change in the quality?	The current achievement level of the indicator.	The trigger level at which the impact is escalated to the Trust .	The set of actions to be taken once the trigger is breached.

Maximum risk score (overall)

0

	Date	Comments
Approval and		
comments -		
Medical Director /		
Director of Nursing		

Infection rate e.g MRSA
Medication errors
Slips, trips and falls
Adverse events e.g SUIs
Readmission rate
Mortality rate
Average length of stay
Patient satisfaction (discharge survey)
Patient complaints
Waiting times
Sickness and absence levels
Turnover rate
Staff satisfaction/ safety



TB2018.80 Appendix 1

Appendix 2: Quality Impact Assessment - Escalation proforma

To be completed when the initial impact assessment indicates a high risk (16 or above) and a more detailed assessment is required.

On identification of a high risk business case, commissioning decision or business plan this proforma must be submitted along with the business case to inform the decision making process and ensure informed choice. A copy of the complete impact assessment must be submitted to the next available quality and outcomes committee to ensure scrutiny from a quality perspective.

Background and context of the business case/plan/decision for approval
What are the benefits?
What are the risks if the business case is not approved?
What are the high risks that the initial impact assessment indicates to certain groups or quality?
What plans are in place to ensure identified risks are mitigated?
After mitigation, what are the remaining residual risks?
Assessment completed by
Name:
Position:
Date:
Line Manager Review
Name:
Position:
Date: